After a jump in its stock price of more than 9 percent on Tuesday, stock in Biogen, the Cambridge-based biotech giant, fell nearly 3 percent in trading on Wednesday.

The roller coaster follows a Wall Street Journal report this week that Biogen could be a takeover target. Biogen leadership is not commenting.

Peter Cohan, visiting lecturer on strategy and entrepreneurship at Babson College, joined Morning Edition to discuss